Licensing opportunities Leverage the existing history of licensing with European partners for vibegron and potential expansion into additional regional markets or combinatory urology therapies. Engage partners seeking to broaden their urology portfolio or accelerate regulatory timelines in new jurisdictions.

Product portfolio growth Opportunity to cross-sell or co-develop next generation urology therapies building on GEMTESA foundation and the gene therapy program URO-902, targeting unmet needs in overactive bladder and related urological conditions.

Operational footprint With a substantial US and Europe team and prior commercial launches, there is capacity to scale field force for new indications, training programs, and payer engagement to support rapid uptake of potential new therapies.

Strategic partnerships Identify opportunities with Sumitovant BioPharma and SMPA-backed entities to accelerate development timelines, access funding for late-stage trials, and align on global commercialization strategies across markets.

Market signals Industry recognition for Best Workplaces and a track record of launches suggests a favorable environment for recruiting experienced urology specialists and securing top-tier talent to support expansion and clinical trial execution.